Curis (NASDAQ:CRIS) Rating Lowered to “Strong Sell” at Wall Street Zen

Curis (NASDAQ:CRIS) was downgraded by equities research analysts at Wall Street Zen to a “strong sell” rating in a report issued on Saturday.

Several other equities research analysts have also weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $43.00 price target (up from $17.00) on shares of Curis in a research note on Friday, July 24th. Finally, Zacks Research upgraded Curis from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $43.00.

Curis Stock Performance

Shares of CRIS stock opened at $4.02 on Friday. The stock has a 50 day moving average of $6.61 and a two-hundred day moving average of $12.26. Curis has a 12 month low of $3.61 and a 12 month high of $39.00. The company has a market capitalization of $7.84 million, a P/E ratio of -0.17 and a beta of 3.13.

Curis (NASDAQ:CRIS) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) EPS for the quarter, missing the consensus estimate of ($6.53) by ($18.47). Sell-side analysts predict that Curis will post -33.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CRIS. Armistice Capital LLC raised its position in shares of Curis by 8.7% during the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after acquiring an additional 78,265 shares during the last quarter. Maverick Capital Ltd. boosted its position in shares of Curis by 7.8% in the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after purchasing an additional 49,554 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Curis by 52.2% in the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 125,823 shares during the last quarter. Flputnam Investment Management Co. acquired a new stake in shares of Curis during the second quarter worth $128,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of Curis by 2,883,237.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 230,659 shares during the period. 29.97% of the stock is currently owned by institutional investors and hedge funds.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.